On November 21, 2019, Amgen acquired from Celgene Corporation the worldwide rights to Otezla® (apremilast).
Effective November 21, 2019, refer to the Amgen's Terms of Use relating to the access of Amgen websites, applications and digital services and Privacy Statement concerning the collection and use of your personal information.
For information collected by Celgene prior to November 21, 2019, refer to Celgene's Terms of Use and Privacy Policy.
Oral Ulcers in Behçet's Disease
Behçet’s Disease, also referred to as Behçet’s Syndrome, is classified as a variable vessel vasculitis.1
Oral ulcers can be bothersome and painful6,7
Major-type oral aphthous ulcer10
Oral aphthous ulcer11
Herpetiform ulceration11
References: 1. Leonardo NM, McNeil J. Int J Rheumatol. 2015;2015:945262. 2. International Study Group for Behçet’s Disease. Criteria for diagnosis of Behçet’s disease. Lancet. 1990;335(8697):1078-1080. 3. Alpsoy E, Donmez L, Onder M, et al. Br J Dermatol. 2007;157(5):901-906. 4. Yazici Y, Yazici H, eds. Behçet’s Syndrome. New York, NY: Springer; 2010:7-34. 5. Zeidan MJ, Saadoun D, Garrido M, et al. Autoimmun Highlights. 2016;7(1):4. 6. Alpsoy E. J Dermatol. 2016;43(6):620-632. 7. Melikoglu M, Melikoglu M. Acta Reumatol Port. 2014;39:46-53. 8. Bang D, Hur W, Lee ES, Lee S. J Dermatol. 1995;22(12):926-929. 9. Ambrose NL, Haskard DO. Nat Rev Rheumatol. 2013;9(2):79-89. 10. Lee S, Bang D, Lee ES, Sohn S, eds. Behçet’s Disease: A Guide to its Clinical Understanding Textbook and Atlas. Heidelberg, Germany: Springer-Verlag; 2001:19-50. 11. Gualtierotti R, Marzano AV, Spadari F, et al. J Clin Med. 2019;8(1):1-19; http://creativecommons.org/licenses/by/4.0/. 12. Otezla [package insert]. Thousand Oaks, CA: Amgen Inc.
Otezla® (apremilast) is indicated for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.
Otezla is indicated for the treatment of adult patients with active psoriatic arthritis.
Otezla is indicated for the treatment of adult patients with oral ulcers associated with Behçet’s Disease.
Contraindications
Warnings and Precautions
Adverse Reactions
Use in Specific Populations
Please click here for Full Prescribing Information.
Otezla® (apremilast) is indicated for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.
Otezla is indicated for the treatment of adult patients with active psoriatic arthritis.
Otezla is indicated for the treatment of adult patients with oral ulcers associated with Behçet’s Disease.
Contraindications
Warnings and Precautions
Adverse Reactions
Use in Specific Populations
Please click here for Full Prescribing Information.